Jun Jia

Nov 7, 2024 | mdpi.com | Jun Jia

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Mar 28, 2024 | onlinelibrary.wiley.com | Yi Liang |Xiao Liao |Jun Jia |Yi Yin

CONFLICT OF INTEREST STATEMENT The authors declare no potential conflicts of interest. Supporting Information Filename Description imm13787-sup-0001-Figures.docWord document, 9.8 MB Figure S1: K33 only mutant ubiquitin had no effect on BMDC viability. BMDCs were treated with cisplatin (50 μg/mL) or K33 only mutant ubiquitin (K33O, 15 μM) for 12–16 h. Then, cell viability was determined by CCK8 assay. One representative from three independent experiments is shown.

Feb 11, 2024 | pericles.pericles-prod.literatumonline.com | Peng Wang |Bo Liu |Jun Jia

Heterotopic bone occurs after burns, trauma and major orthopedic surgery, which cannot be completely cured by current treatments. The development of new treatments requires more in-depth research into the mechanism of HO. Available evidence suggests that miR-21-5p plays an important role in bone formation. However, its mechanism in traumatic HO is still unclear.

Jul 23, 2023 | mdpi.com | Jun Jia |Ke He |Liang Xue |Chao Q. Jiang

This is an early access version, the complete PDF, HTML, and XML versions will be available soon.